Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Cancer cell or component thereof
Reexamination Certificate
2006-01-10
2006-01-10
Canella, Karen A. (Department: 1642)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Cancer cell or component thereof
C424S278100, C514S002600, C514S252010, C514S274000, C514S506000, C514S510000, C514S529000, C514S532000, C514S533000, C514S545000, C514S555000, C514S556000, C514S557000, C514S561000, C514S567000, C514S568000, C514S576000, C514S579000, C514S649000, C514S675000, C514S677000, C514S681000, C514S685000, C514S688000, C514S694000, C514S699000, C514S701000
Reexamination Certificate
active
06984389
ABSTRACT:
The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an α-2-macroglobulin (α2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an α2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or α2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality.
REFERENCES:
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5736146 (1998-04-01), Cohen
patent: 5750119 (1998-05-01), Srivastava
patent: 5830464 (1998-11-01), Srivastava
patent: 5837251 (1998-11-01), Srivastava
patent: 5869058 (1999-02-01), Cohen
patent: 5935576 (1999-08-01), Srivastava
patent: 5961979 (1999-10-01), Srivastava
patent: 5985270 (1999-11-01), Srivastava
patent: 5997873 (1999-12-01), Srivastava
patent: 6017540 (2000-01-01), Srivastava
patent: 6030618 (2000-02-01), Srivastava
patent: 6048530 (2000-04-01), Srivastava
patent: 2002/0037290 (2002-03-01), Armen
patent: 2002/0192230 (2002-12-01), Srivastava
patent: WO 94/14976 (1994-07-01), None
patent: WO 95/34638 (1995-12-01), None
patent: WO 97/06821 (1997-02-01), None
patent: WO 99/50303 (1999-10-01), None
patent: WO 00/54801 (2000-09-01), None
patent: WO 01/91787 (2001-06-01), None
patent: WO 02/11669 (2002-02-01), None
patent: WO 02/32923 (2002-04-01), None
patent: WO 02/34205 (2002-05-01), None
patent: PCT/US03/13967 (2003-05-01), None
Abstract of Hoover et al (Cancer Immunology, immunotherapy, 1990, vol. 31, pp. 121-127).
Abstract of Simizu et al (Bioscience, Biotechnology and Biochemistry, 1994, vol. 58, pp. 1549-1552).
Riordan et al (Oncogene, 1998, vol. 16, pp. 153-1542).
Carlo-Stella et al (Blood, 1996, vol. 88, pp. 3091-3100).
Abstract of Jacob et al, Indian J Cancer, 2002, vol. 39, pp. 61-65.
Abstract of Mauro et al, Curr Opin Oncol, 2001, vol. 13, pp. 3-7.
Abstract of Kolialexi et al, Anticancer Res, 1998, vol. 18(4A), pp. 2359-2364.
Abstract of Dorak et al (Leuk Lymphoma, 1994, vol. 12, pp. 211-222).
Abstract of Bortin et al (Blood, 1987, vol. 70, pp. 227-232).
Abstract of Haas et al (Nature, 1992, vol. 359, pp. 414-416).
Nishimura et al (Cancer Chemother Pharmacol, 2000, vol. 46 (suppl.), pp. S52-S61).
U.S. Appl. No. 60/223, 133.
U.S. Appl. No. 10/427,857, filed May 1, 2003, Srivastava.
U.S. Appl. No. 10/131,961, filed Apr. 25, 2002, Srivastava.
U.S. Appl. No. 10/131,937, filed Apr. 25, 2002, Srivastava.
U.S. Appl. No. 10/126,368, filed Apr. 19, 2002, Srivastava.
U.S. Appl. No. 09/693,643, filed Oct. 20, 2000, Srivastava.
Andersen P., 1994, “Effective vaccination of mice againstMycobacterium tuberculosisinfection with a soluble mixture of secreted mycobacterial proteins,” Infect. Immun. 62(6):2536-2544.
Anthony et al., 1999, “Priming of CD8+ CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusion molecule,” Vaccine 17(4):373-383.
Asea et al., 2000, “HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstratiing its dual role as a chaperone and cytokine,” Nature Medicine 6:435-442.
Banchereau et al., 1998, “Dendritic cells and the control of immunity,” Nature 392:245-252.
Barrios et al., “Heat shock proteins as carrier molecules: in vivo helper effect mediated byEscherichia coliGroEL and Dna K proteins requires cross-linking with antigen,” Clin. Exp. Immunol. 98(2):229-233.
Barrios et al., 1992, “Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Calmette Guerin priming,” Eur. J. Immunol. 22(6):1365-1372.
Basu, S. et al., 2001, “CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin,” Immunity 14(3):303-313.
Basu et al., 2000, “Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway,” Int. Immunol. 12(11):1539-1546.
Basu S et al., 1999, “Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity,” J. Exp. Med. 189(5):797-802.
Berke et al., 2000, “Peptides spanning the junctional region of both the abl/bcr and the bcr/abl proteins bind common HLA class I molecules,” Leukemia 14:419-426.
Binder et al., 2001, “Adjuvanticity of alpha 2-macroglubolin, an independent ligand for the heat shock protein receptor CD91,” J. Immunol. 166(8):4968-4972.
Binder et al., 2000, “CD91: a receptor for heat shock protein gp96,” Nat. Immunol. 1(2):151-155.
Birkenmeier, G., 2001, “Targeting the Proteinase Inhibitor and Immune Modulatory Function of Human α2-Macroglobulin,” Mod. Asp. Immunobiol., 2(1):32-36.
Blachere et al., 1997, “Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity,” J. Exp. Med. 186(8):1315-1322.
Blander et al., 1993, “Major cytoplasmic membrane protein ofLegionella pneumophila, a genus common antigen and member of the hsp 60 family of heat shock proteins, induces protective immunity in a guinea pig model of Legionnaires' disease,” J. Clin. Invest. 91(2):717-723.
Breoler et al., 1999, “In vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins,” J. Immunol. 162:3141-3147.
Chen et al., 2000, “Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene,” Cancer Res. 60:1035-1042.
Chen et al., 1999, “Human 60-kDa heat-shock protein: a danger signal to the innate immune system,” J. Immunol. 162:3212-3219.
Chronic Myeloid Leukemia Trialists' Collaborative Group, 1997, J. Natl. Cancer Inst. 89(21):1616-1620.
Chu et al., 1994, “Adjuvant-free in vivo targeting: Antigen delivery by alpha 2-macroglobulin enhances antibody formation,” J. Immunol. 152(4):1538-1545.
Chu et al., 1994, “Alpha 2-macroglobulin: a sensor for proteolysis,” Ann. NY Acad. Sci. 737:291-307.
Chu et al., 1994, “Alpha 2-macroglobulin, complement, and biologic defense: antigens, growth factors, microbial proteases, and receptor ligation,” Lab. Invest. 71(6):792-812.
Chu et al. 1993, “Receptor-mediated antigen delivery into macrophages: Complexing antigen to alpha 2-macroglobulin enhances presentation to T cells,” J. Immunol. 150(1):48-58.
Craig et al., 1993, “Chaperones: helpers along the pathways to protein folding,” Science 260:1902-1903.
Curley et al., 1995, “Identification and screening of 416 patients with chronic hepatitis at high risk to develop hepatocellular cancer,” Ann. Surg. 222(3):375-383.
Dazzi et al., 1999, “Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogenic stem cell transplant: Where we now stand,” Experimental Hematology 27:1477-1486.
Del Giudice et al., 1994, “Hsp70: a carrier molecule with built-in adjuvanticity,” Experientia 50(11-12):1061-1066.
Druker et al., 2001, “Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome,” New England J. Med. 344(14):1038-1042.
Druker et al., 2001, “Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia,” New England J. Med. 344(14):1031-1037.
Drucker and Lydon, 2000, “Lessons learned from the
Canella Karen A.
Jones Day
University of Connecticut Health Center
LandOfFree
Using heat shock proteins to improve the therapeutic benefit... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Using heat shock proteins to improve the therapeutic benefit..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Using heat shock proteins to improve the therapeutic benefit... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3554402